ESRRA and Parkinson disease: It was noted that ERRα inverse agonist XCT 790 has been shown to clear α-synuclein aggregates in an autophagy-dependent, mTOR-independent manner, offering potential neuroprotective effects in Parkinson’s disease models by enhancing autophagosome biogenesis [139].